Phibro Animal Health Corporation $PAHC Stock: Profund Advisors LLC Increases Stake

Profund Advisors LLC boosted its holdings in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 229.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,263 shares of the company’s stock after purchasing an additional 18,291 shares during the quarter. Profund Advisors LLC’s holdings in Phibro Animal Health were worth $939,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sterling Capital Management LLC increased its position in Phibro Animal Health by 864.9% in the 3rd quarter. Sterling Capital Management LLC now owns 714 shares of the company’s stock worth $26,000 after buying an additional 640 shares during the period. KBC Group NV bought a new stake in shares of Phibro Animal Health in the first quarter valued at approximately $29,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Phibro Animal Health by 14.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,851 shares of the company’s stock valued at $137,000 after acquiring an additional 498 shares during the period. Inspire Investing LLC boosted its position in shares of Phibro Animal Health by 84.9% in the third quarter. Inspire Investing LLC now owns 4,219 shares of the company’s stock valued at $151,000 after acquiring an additional 1,937 shares during the period. Finally, James Investment Research Inc. acquired a new stake in shares of Phibro Animal Health in the third quarter worth $224,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PAHC. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 18th. Weiss Ratings raised shares of Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $47.67.

Phibro Animal Health Stock Down 2.8%

NASDAQ PAHC opened at $37.65 on Wednesday. Phibro Animal Health Corporation has a twelve month low of $28.25 and a twelve month high of $60.08. The stock has a market cap of $1.53 billion, a PE ratio of 12.07 and a beta of 0.42. The firm has a 50-day simple moving average of $37.09 and a 200 day simple moving average of $41.10. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.27 and a current ratio of 2.96.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, August 26th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.14. Phibro Animal Health had a return on equity of 37.86% and a net margin of 6.57%. The firm had revenue of $396.75 million for the quarter, compared to analyst estimates of $381.18 million. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. On average, research analysts forecast that Phibro Animal Health Corporation will post 3.49 EPS for the current year.

About Phibro Animal Health

Phibro Animal Health Corporation develops, manufactures and sells products designed to support the health, nutrition and productivity of food-producing animals. Its offerings include animal health products, vaccines, medicated feed additives, nutritional specialties and performance products used in livestock, poultry and aquaculture.

The company’s products are intended to help prevent and manage disease, improve animal well-being and support efficient food production. Phibro serves producers, veterinarians, feed manufacturers and distributors through a portfolio that includes pharmaceuticals, vaccines, mineral and nutritional supplements, and other feed and water solutions.

Phibro Animal Health markets its products internationally across a broad range of geographic regions, including North America, Latin America, Europe, Asia-Pacific and other global markets.